The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02629952




Registration number
NCT02629952
Ethics application status
Date submitted
3/12/2015
Date registered
15/12/2015

Titles & IDs
Public title
Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes
Scientific title
Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes
Secondary ID [1] 0 0
H0014873
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Blueberry Tea

Experimental: Blueberry Tea - 3 cups of blueberry tea per day x 4 weeks

No intervention: No Treatment - No Treatment


Other interventions: Blueberry Tea
Blueberry Tea

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Improvement in Glucose Tolerance after 4 weeks of drinking blueberry tea.
Timepoint [1] 0 0
4 weeks
Secondary outcome [1] 0 0
Improvement in Hemoglobin A1c (HbA1c) levels after 4 weeks of drinking blueberry tea.
Timepoint [1] 0 0
4 weeks.
Secondary outcome [2] 0 0
Improvement in fasting Serum Lipid (cholesterol, HDL, LDL,triglycerides) levels after 4 weeks of drinking blueberry tea.
Timepoint [2] 0 0
4 weeks
Secondary outcome [3] 0 0
Improvement in fasting serum pro-inflammatory cytokine (IL-6, IL-1b, CRP, TNFa) levels after 4 weeks of drinking blueberry tea.
Timepoint [3] 0 0
4 weeks
Secondary outcome [4] 0 0
Improvement in fasting serum albumin levels after 4 weeks of drinking blueberry tea..
Timepoint [4] 0 0
4 weeks
Secondary outcome [5] 0 0
Fasting serum electrolytes (Na, K, Cl, HCO3).
Timepoint [5] 0 0
4 weeks
Secondary outcome [6] 0 0
Improvement in Resting Blood Pressure (central and brachial blood pressure) after 4 weeks of drinking blueberry tea.
Timepoint [6] 0 0
4 weeks
Secondary outcome [7] 0 0
Improvement in resting Augmentation Index after 4 weeks of drinking blueberry tea.
Timepoint [7] 0 0
4 weeks
Secondary outcome [8] 0 0
Improvement in large artery stiffness after 4 weeks of drinking blueberry tea.
Timepoint [8] 0 0
4 weeks

Eligibility
Key inclusion criteria
* Aged 18-75 years.
* Normal to overweight (BMI 19-35 kg/m2).
* On lifestyle or metformin only diabetes treatment.
* Normotensive (seated brachial blood pressure <160/100 mmHg).
* No history of T2D (e.g. fasting plasma glucose <7.0mM); or with clinically diagnosed T2D on metformin or lifestyle intervention only (e.g. fasting plasma glucose =7.0mM, HbA1c).
* Willing to drink blueberry tea for 4 weeks (3 times per day with meals).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Age <18 yrs or >76 yrs
* Morbidly obese with a BMI =36 kg/m2
* Not on lifestyle and/or metformin only treatment for diabetes (e.g. insulin injections, sulphonylureas).
* History of myocardial infarction or stroke
* History of malignancy within past 5 years (except for non-melanoma skin cancers)
* Current smoker
* History of severe liver disease
* History of drug or alcohol abuse
* Elective major surgery during the course of the study
* Pregnancy/lactation
* Currently consuming (or have regularly consumed in the past 2 months) blueberry tea, or supplements containing blueberries, blueberry leaves, raspberry leaves, spearmint or cinnamon.
* Participation or intention to participate in another clinical research study during the study period.
* Not willing to consume blueberry tea for 4 weeks.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS
Recruitment hospital [1] 0 0
Menzies Institute for Medical Research - Hobart
Recruitment postcode(s) [1] 0 0
7000 - Hobart

Funding & Sponsors
Primary sponsor type
Other
Name
Menzies Institute for Medical Research
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michelle A Keske, PhD
Address 0 0
Menzies Institute for Medical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Michelle A Keske, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 3 6226 2669
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.